Halozyme Therapeutics (HALO)
77.82
-0.78 (0.99%)
Upcoming Events
Latest Headlines
Benchmark Reiterates Buy Rating on Halozyme Therapeutics (HALO) on 'Solid Partnership Momentum'
July 21, 2026 9:23 AM - StreetInsider
Halozyme and Incyte sign drug delivery licensing agreement
July 20, 2026 8:00 AM - StreetInsider
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology
July 20, 2026 8:00 AM - PR NewsWire
Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Fund Series (“ETF Series”) and Exchange Traded Funds (“ETFs”)
July 14, 2026 4:00 PM - BizWire
Form 4 HALOZYME THERAPEUTICS, For: Jul 08 Filed by: Torley Helen
July 9, 2026 5:20 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: Jun 30 Filed by: RAMSAY DAVID A
July 2, 2026 4:46 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: Jul 01 Filed by: Snellgrove Darren
July 2, 2026 4:44 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: Jul 01 Filed by: Connaughton Bernadette
July 2, 2026 4:42 PM - SEC Filing
Form 8-K HALOZYME THERAPEUTICS, For: Jun 30
July 2, 2026 4:10 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: Jun 29 Filed by: Krishnan Mahesh
June 30, 2026 5:25 PM - SEC Filing
Halozyme names David Ramsay as president of drug delivery
June 30, 2026 4:02 PM - StreetInsider
Halozyme Appoints David Ramsay as President Drug Delivery
June 30, 2026 4:02 PM - PR NewsWire
Form 144 HALOZYME THERAPEUTICS, Filed by: Krishnan Mahesh
June 29, 2026 4:41 PM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)
June 16, 2026 6:43 AM - StreetInsider
Form 4 HALOZYME THERAPEUTICS, For: Jun 12 Filed by: Snyder Mark Howard
June 15, 2026 4:10 PM - SEC Filing
Halozyme expects minimal Medicare pricing impact on royalties through 2035
June 15, 2026 6:01 AM - StreetInsider
Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029
June 15, 2026 6:00 AM - PR NewsWire
Form 3 HALOZYME THERAPEUTICS, For: Jun 08 Filed by: Snellgrove Darren
June 9, 2026 4:59 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: Jun 01 Filed by: Torley Helen
June 3, 2026 8:07 PM - SEC Filing
Benchmark Reiterates Buy Rating on Halozyme Therapeutics (HALO) on Near-Term Potential
June 3, 2026 9:02 AM - StreetInsider
Form 4 HALOZYME THERAPEUTICS, For: Jun 01 Filed by: Connaughton Bernadette
June 2, 2026 5:20 PM - SEC Filing
JPMorgan Reinstates Halozyme Therapeutics (HALO) at Neutral
May 20, 2026 4:31 AM - StreetInsider
Form 144 HALOZYME THERAPEUTICS, Filed by: LaBrosse Nicole
May 15, 2026 4:19 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: May 11 Filed by: Torley Helen
May 13, 2026 5:50 PM - SEC Filing
Increasing unusual call option volume: MRAM HALO DGXX DT SGI CM KOPN
May 13, 2026 5:40 AM - StreetInsider
Halozyme Therapeutics (HALO) PT Lowered to $93 at Morgan Stanley
May 12, 2026 8:35 AM - StreetInsider
Halozyme Therapeutics (HALO) Reiterated at Market Outperform by Citizens on Beating Q1 Estimates
May 12, 2026 5:47 AM - StreetInsider
Halozyme Therapeutics (HALO)
May 11, 2026 4:20 PM - StreetInsider
Form 144 HALOZYME THERAPEUTICS, Filed by: Torley Helen
May 11, 2026 4:11 PM - SEC Filing
Form 10-Q HALOZYME THERAPEUTICS, For: Mar 31
May 11, 2026 4:11 PM - SEC Filing
Form 8-K HALOZYME THERAPEUTICS, For: May 11
May 11, 2026 4:07 PM - SEC Filing
Halozyme Therapeutics (HALO) Tops Q1 EPS by 6c
May 11, 2026 4:03 PM - StreetInsider
HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
May 11, 2026 4:01 PM - PR NewsWire
Form 4 HALOZYME THERAPEUTICS, For: May 05 Filed by: Posard Matthew L.
May 7, 2026 7:05 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: May 05 Filed by: Krishnan Mahesh
May 7, 2026 7:04 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: May 05 Filed by: Lang James Paul
May 7, 2026 7:04 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: May 05 Filed by: Henderson Jeffrey William
May 7, 2026 7:03 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: May 05 Filed by: DUNCAN BARBARA GAYLE
May 7, 2026 7:02 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: May 05 Filed by: Connaughton Bernadette
May 7, 2026 7:02 PM - SEC Filing
Form 8-K HALOZYME THERAPEUTICS, For: May 05
May 7, 2026 4:19 PM - SEC Filing
Halozyme partners with GSK for subcutaneous cancer drug development
May 7, 2026 9:00 AM - StreetInsider
Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets
May 7, 2026 9:00 AM - PR NewsWire
Halozyme partners with Oruka for psoriasis drug development deal
May 6, 2026 8:01 AM - StreetInsider
Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology
May 6, 2026 8:00 AM - PR NewsWire
Form 4 HALOZYME THERAPEUTICS, For: May 01 Filed by: Connaughton Bernadette
May 5, 2026 5:05 PM - SEC Filing
Form 144 HALOZYME THERAPEUTICS, Filed by: Connaughton Bernadette
May 1, 2026 4:46 PM - SEC Filing
Halozyme to Report First Quarter 2026 Financial and Operating Results
April 30, 2026 4:30 PM - PR NewsWire
Form SCHEDULE 13G HALOZYME THERAPEUTICS, Filed by: VANGUARD CAPITAL MANAGEMENT LLC
April 30, 2026 10:40 AM - SEC Filing
Form 8-K HALOZYME THERAPEUTICS, For: Apr 30
April 30, 2026 8:15 AM - SEC Filing
Halozyme names Darren Snellgrove as chief financial officer
April 30, 2026 8:00 AM - StreetInsider
Halozyme Appoints Darren Snellgrove as Chief Financial Officer
April 30, 2026 8:00 AM - PR NewsWire
Halozyme Therapeutics (HALO) PT Raised to $95 at H.C. Wainwright
April 29, 2026 6:57 AM - StreetInsider
Form 8-K HALOZYME THERAPEUTICS, For: Apr 22
April 24, 2026 4:08 PM - SEC Filing
Full Article List
